摘要
目的分析比阿培南治疗肝硬化自发性腹膜炎的临床疗效、90 d存活率及安全性。方法回顾性分析2017年9月至2021年9月在本院住院接受诊治的肝硬化自发性腹膜炎患者共63例,按随机数字表法分组,将其分为观察组(比阿培南)和对照组(头孢曲松钠),分析比较两组的临床疗效、90 d存活率及不良反应发生情况。结果观察组总有效率(30/32,93.75%)明显优于对照组(24/31,77.41%),但差异无统计学意义(χ^(2)=2.225,P>0.05);观察组90 d存活率(27/32,84.38%)明显高于对照组(18/31,58.06%),两组比较差异有统计学意义(χ^(2)=5.341,P<0.05);两组患者用药过程中的不良反应发生率均低,差异无统计学意义(χ^(2)=0.355,P>0.05)。结论比阿培南治疗肝硬化自发性腹膜炎疗效显著且安全,90 d存活率高,故临床值得推广应用。
Objective To investigate the clinical efficacy,90-day survival rate,and safety of biapenem in the treatment of spontaneous bacterial peritonitis(SBP)accompanying with hepatocirrhosis.Methods A total of 63 patients with SBP hospitalized and treated at Zhuji People's Hospital from September 2017 to September 2021 were retrospectively included in this study.Grouping by random number table method,patients were divided into the observation group and the control group,according to different antibiotic treatments,namely biapenem and ceftriaxone,respectively.The clinical efficacy,90-day survival rate,and the incidence of adverse effects were compared between the two groups.Results The total effective rate of the observation group(30/32,93.75%)was higher compared to the control group(24/31,77.41%),but the difference was not statistically significant(χ^(2)=2.225,P>0.05).The 90-day survival rate of the observation group(27/32,84.38%)was significantly higher compared to the control group(18/31,58.06%),and the difference was statistically significant(χ^(2)=5.341,P<0.05).The incidence of adverse events during drug administration was low in both groups,and the difference was not statistically significant(χ^(2)=0.355,P>0.05).Conclusion The efficacy and safety profile of biapenem in treating SBP is remarkable,leading to higher 90-day survival compared to the standard treatment.Therefore,this study proposes the use of biapenem in clinical practice.
出处
《浙江临床医学》
2023年第6期859-862,共4页
Zhejiang Clinical Medical Journal
关键词
比阿培南
头孢曲松钠
肝硬化
自发性腹膜炎
临床疗效
Biapenem
Ceftriaxone
Hepatocirrhosis
Spontaneous bacterial peritonitis
Efficacy
